

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/829,273	04/09/2001	Wayne R. Myers	CRNC.78765	8119
46169 SHOOK HAR	7590 08/28/2007 RDY & BACON L.L.P.		EXAM	INER
Intellectual Property Department			SMITS, TALIVALDIS IVARS	
2555 GRAND BOULEVARD KANSAS CITY, MO 64108-2613			ART UNIT	PAPER NUMBER
			2626	
			MAIL DATE	DELIVERY MODE
			08/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	- I	T			
	Application No.	Applicant(s)			
	09/829,273	MYERS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Talivaldis Ivars Smits	2626			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING Description of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status	•				
1) Responsive to communication(s) filed on <u>04 April 2007</u> .					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C _. D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-6,8-26,28-46 and 48-60</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) 1-6, 8-26, 28-46, and 48-60 is/are re	jected.				
7) Claim(s) is/are objected to.	or election requirement				
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.					
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail D 5) Notice of Informal F 6) Other:				

Application/Control Number: 09/829,273

Art Unit: 2626

DETAILED ACTION

Response to Amendment

1. In response to the Office Action of 1/4/2007 applicant has submitted an Amendment, filed 4/4/2007 arguing to traverse the claim rejections.

Response to Arguments

2. Applicant's arguments with respect to claims 1-6, 8-26, 28-46 and 48-60 have been considered but are most in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 1-6, 8-9, 11-16, 20-26, 28-29, 31-36, 40-46, 48-49, 51-56, and 60 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kim Binsted *et al.* ("Generating Personalised Patient Information Using the Medical Record", 1995), hereafter Binsted.

As to claim 1, 21 and 41, Binsted teaches:

receiving a medical test result for a type of medical test ("A list of tests and measurements, each with data and result", p. 32);

if the medical test result will be automatically interpreted independent of clinician input, identifying at least one template associated with the type of medical test; selecting a template matching the medical test result; and outputting a plain language explanation based on the selected template (cholesterol level template on p. 36).

Binsted does not explicitly teach determining if the medical test result will be automatically interpreted independent of clinician input or if the medical test result will be interpreted using clinician input. However, Binsted suggests this by teaching that "the knowledge base, the record, and the text plans used to generate the explanations must all be easily modified by medical personnel, p. 30).

It would have been obvious to one of ordinary skill at the time of invention to have clinician input because Binsted teaches that "The system must not 'put words in the doctor's mouth" (p. 30).

As to claims 2, 22 and 42, Binsted teaches identifying at least one diagnosis output with an explanation associated with the type of medical test comprises identifying a set of a plurality of templates associated with the type of medical test ("The text generator uses domain-dependent text plans", wherein "There can be several text plans of the same name", p. 32 and 33).

Application/Control Number: 09/829,273

Art Unit: 2626

As to claims 3, 23 and 43, Binsted teaches each template of the identified set corresponds to a range of medical test result values ("combining general explanations with reminders of patient specific data", and "cholesterol level" example on p. 36).

As to claims 4, 24 and 44, Binsted teaches selecting templates which correspond to the range encompassing the medical test result ("cholesterol level" example, p. 36).

As to claims 5, 25 and 45, Binsted teaches each template of the identified set corresponds to a medical test result value ("cholesterol level" example, p. 36).

As to claims 6, 26 and 46, Binsted teaches determining a template corresponding to the medical test result value ("hyperlipidaemia" example, p. 36).

As to claims 8, 28 and 48, Binsted suggests if the medial test result will be interpreted using clinician input distributing the medical test result to the clinician and receiving clinician input, the input matching the medical test result to a template (It is essential that a medical expert be able to check through the generated explanations, p. 30).

As to claims 9, 29 and 49, Binsted suggests recording the input of the clinician ("the knowledge base, the record, and the text plans used to generate the explanations must all be easily modified by medical personnel, p. 30).

As to claim 12, 32 and 52, Binsted teaches inserting data into the selected template at the placeholder ("This plan will apply only to a measurement which is in the patient record, and will generate (as part of a larger explanation) the specifications of a sentence giving the measurement value and date", p. 33).

As to claims 13, 33 and 53, Binsted teaches the data is numerical value for the medical test result ("Your cholesterol level was last measured at 3.8 mmol/L", p. 33).

As to claims 14, 34 and 54, Binsead does not explicitly teach the step of determining whether the selected template can be sent directly to the patient. However, Binsted suggests this by teaching that "the knowledge base, the record, and the text plans used to generate the explanations must all be easily modified by medical personnel, p. 30).

It would have been obvious to one of ordinary skill at the time of invention to have a clinician first check the selected template before sending it to the patient because Binsted teaches that "The system must not 'put words in the doctor's mouth'" (p. 30).

As to claims 15, 35 and 55, Binsted teaches the outputting includes sending a message to a storage unit and adapting the selected template for viewing via a web browser (implied by "the user starts from a hypertext version of their record, and can click on any of the issues in that record to obtain further information", p. 34).

As to claims 16, 36 and 56, Binsted teaches the outputted plain language explanation is textual (see rejection to claim 1).

As to claims 20, 40 and 60, Watrous teaches the step of distributing the results to a physician for review prior to the step of outputting a plain language explanation based on the selected template (see rejection to claim 14 above).

5. Claims 10, 17-19, 30, 37-39, 50, and 57-59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Binsted as applied to claims 1, 21 and 41 above in view of Rapaport et al. (5,926,526), hereafter Rapaport.

As to claims 10, 30 and 50 Binsted does not teach receiving patient information and comparing the patient information against a list of patients having authorization to receive the medical test result.

However, Rapaport teaches having a patient enter his identification number, along with a password, giving the patient access to the system (co. 7, lines 48-57).

Application/Control Number: 09/829,273

Art Unit: 2626

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to combine the automatic diagnosis features of Binsted with the authorization requirement of Rapaport to supply only the patient or her

authorized representative(s) with patient;s specific medical test results.

As to claims 17, 37 and 57, Binsted does not teach the outputted plain language explanation is audible.

However, Rapaport teaches the outputted plain language explanation is outputted via a telephone (col. 5, lines 1-2)

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to combine the automatic diagnosis features of Binsted with the audible output of Rapaport to supply the patient with specific medical test results, that the patient is able to understand in a secure environment without having to have the medical provider to continually attempt to contact the patient, saving both time and resources of the medical provider and patient, as taught by Rapaport(col. 1, lines 43-58).

As to claims 18, 38 and 58, Binsted does not teach the plain language explanation is delivered by an automated phone system.

However, Rapaport teaches the outputted plain language explanation is outputted via a telephone with an automated user interface (col. 5, lines 1-2)

Art Unit: 2626

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to combine the automatic diagnosis features of Binsted with the audible output of Rapaport to supply the patient with specific medical test results, that the patient is able to understand in a secure environment without having to have the medical provider to continually attempt to contact the patient, saving both time and resources of the medical provider and patient, as taught by Rapaport (col. 1, lines 43-58).

As to claims 19, 39 and 59, Binsted does not teach the plain language explanation is delivered by a wireless device.

However, Rapaport teaches the output can be a wireless communication device, (col. 5, lines 11-13).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to combine the automatic diagnosis features of Watrous with the output of Rapaport et al. to supply the patient with specific medical test results, that the patient is able to understand in a secure environment without having to have the medical provider to continually attempt to contact the patient, saving both time and resources of the medical provider and patient, as taught by Rapaport (col. 1, lines 43-58).

Art Unit: 2626

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Talivaldis Ivars Smits whose telephone number is 571-272-7628. The examiner can normally be reached on 8:30 a.m. to 5:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Richemond Dorvil can be reached on 571-272-7602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

8/24/2007

TALIVALDIS IVARS SMITS
PRIMARY EXAMINER